The future of healthcare is digital. While the increasing use of technology will bring opportunities, it will also create new risks for patient safety. Nick Woodier from the Health Services Safety Investigations Body reflects on the implementation of various technologies in healthcare and their impact on patient safety.
New research by the American Heart Association finds that obesity is a factor in almost half of all new cases, with obese individuals significantly more likely to get Type 2 diabetes.
Edward Belgeonne, founder, & CEO Bantham Technologies, discusses how innovative technology is key to hitting net-zero and creating more time to care in the NHS.
The new results led to the South African Government suspending use of AstraZeneca in their vaccination programme, as it is no longer able to stop the mutation - but could still prevent hospitalisation and fatality.
Paul Barrett, TeleTracking UK, explains how automating patient flow and bed management in real-time can transform hospital operations, free up time for nurses to care, reduce stress on caregivers and importantly improve patient outcomes.
AstraZeneca dose efficiency holds at 76% in the three-month period between the first and second dose - suggesting that this time period is good for maximising protection.
Childhood air pollution has been understood as partially responsible for respiratory health - now, researchers are investigating at how exposure can damage cognitive ability later on in life.
According to data collected by 400 healthcare professionals at the worst moment of the US outbreak, the life support machine that acts in place of the heart and lungs is crucial to reducing COVID-19 deaths for the critically ill.
An STFC-funded project, MoleGazer, has successfully implemented astronomical techniques, used for star-gazing, to detect and track the evolution of cancerous moles.
A professor describes severe maternal morbidity in low-income women as a public health crisis - now, Medicaid expansion seems to be improving pregnancy outcomes.
New clinical trial data shows that the Johnson & Johnson vaccine is able to give 66% protection against COVID in one dose - with an 85% efficiency at the standard double-dose.
Phase Three data from the UK trial shows that Novavax still works powerfully against the UK mutation, with a less intense impact on the South African mutation at 60%.
